Prognostic utility of pre-transplantation [ 18 F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage chemotherapy

Br J Haematol. 2020 Jan;188(2):268-271. doi: 10.1111/bjh.16144. Epub 2019 Aug 6.

Abstract

We analysed the outcomes of 62 patients with refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) who had pre-transplantation fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after R-DHAC (rituximab, dexamethasone, high-dose cytarabine, carboplatin) salvage chemotherapy, and were evaluated using Deauville criteria and total lesion glycolysis (TLG). A positive pre-transplantation PET/CT with Deauville score of 5 was associated with shorter progression-free survival (PFS) (P = 0·01), while a Deauville score of 4 was not predictive of outcome. Only pre-transplant TLG was significantly associated with both PFS (P = 0·005) and overall survival (P = 0·03). TLG deserves to be further investigated in prospective studies.

Keywords: 18- fluorodeoxyglucose; autologous stem cell transplantation; diffuse large B-cell lymphoma; positron emission tomography/computed tomography; transplant.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / diagnostic imaging*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • Positron Emission Tomography Computed Tomography / methods*
  • Prognosis
  • Progression-Free Survival
  • Radiopharmaceuticals
  • Rituximab / administration & dosage
  • Salvage Therapy / methods*

Substances

  • Radiopharmaceuticals
  • Cytarabine
  • Fluorodeoxyglucose F18
  • Rituximab
  • Dexamethasone
  • Carboplatin